CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 33 enrolled
Drug / intervention
Teriparatide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01153425
NCT01153425Phase 4Completed
CompareCT.gov

NMR Imaging and Stereological Analysis of Trabecular Bone in Female Subjects 60 and Older at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide

University of Pennsylvania·interventional·Posted Jun 30, 2010·Updated Aug 4, 2017

In Brief

A Phase 4 clinical trial evaluating Virtual Bone Biopsy, Teriparatide, and 1 other intervention for Osteoporosis, Osteopenia. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to apply a novel advanced magnetic resonance imaging methodology to evaluate the response to drug intervention involving two treatment arms of postmenopausal participants with osteoporosis, randomized into either a teriparatide (Forteo™) or zoledronic acid (Reclast™) group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Osteopenia
CountriesUnited States
CollaboratorsEli Lilly and Company, Novartis Pharmaceuticals, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 30, 2010
Enrollment StartJul 1, 2008
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 16.0 years ago

Interventions

Virtual Bone Biopsyother

MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.

Teriparatidedrug

Participants are clinically indicated for treatment.

Zoledronic Aciddrug

Participants are clinically indicated for treatment.